Portage Biotech (NASDAQ:ATON) Now Covered by HC Wainwright

Investment analysts at HC Wainwright initiated coverage on shares of Portage Biotech (NASDAQ:ATON) in a report released on Tuesday, Marketbeat reports. The firm set a “buy” rating and a $2.00 price target on the stock. HC Wainwright’s price objective indicates a potential upside of 387.80% from the company’s current price.

Separately, Weiss Ratings initiated coverage on Portage Biotech in a report on Monday, January 26th. They set a “sell (e+)” rating on the stock. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $2.00.

Portage Biotech Stock Performance

Shares of ATON opened at $0.41 on Tuesday. Portage Biotech has a one year low of $0.36 and a one year high of $15.82. The company has a market capitalization of $3.31 million, a PE ratio of -0.05 and a beta of 0.33.

Portage Biotech (NASDAQ:ATON) last announced its earnings results on Wednesday, January 21st. The company reported ($4.13) earnings per share for the quarter.

About Portage Biotech

Portage Biotech (NASDAQ:ATON) is a biotechnology company focused on acquiring, developing and advancing therapeutic candidates and platform technologies. The company concentrates its development efforts primarily in areas such as oncology, immunology/inflammation and infectious disease, seeking to move programs from discovery and preclinical stages into clinical development through subsidiary companies and collaborative arrangements.

Portage structures its operations to support a diversified pipeline, advancing both small molecules and biologics by funding preclinical research, conducting clinical trials, and managing regulatory interactions.